These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2487155)

  • 1. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes.
    Flejter WL; Li FP; Antman KH; Testa JR
    Genes Chromosomes Cancer; 1989 Nov; 1(2):148-54. PubMed ID: 2487155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma.
    Taguchi T; Jhanwar SC; Siegfried JM; Keller SM; Testa JR
    Cancer Res; 1993 Sep; 53(18):4349-55. PubMed ID: 8364929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.
    Tiainen M; Tammilehto L; Rautonen J; Tuomi T; Mattson K; Knuutila S
    Br J Cancer; 1989 Oct; 60(4):618-26. PubMed ID: 2803935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: correlation between Southern blot and cytogenetic analyses.
    Tiainen M; Kere J; Tammilehto L; Mattson K; Knuutila S
    Genes Chromosomes Cancer; 1992 Mar; 4(2):176-82. PubMed ID: 1373319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal deletion in patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Sugarbaker DJ
    Interact Cardiovasc Thorac Surg; 2009 Jul; 9(1):42-4. PubMed ID: 19346221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma.
    Lu YY; Jhanwar SC; Cheng JQ; Testa JR
    Genes Chromosomes Cancer; 1994 Jan; 9(1):76-80. PubMed ID: 7507705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients.
    Tammilehto L; Tuomi T; Tiainen M; Rautonen J; Knuutila S; Pyrhönen S; Mattson K
    Eur J Cancer; 1992; 28A(8-9):1373-9. PubMed ID: 1325175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma.
    Tiainen M; Tammilehto L; Mattson K; Knuutila S
    Cancer Genet Cytogenet; 1988 Jul; 33(2):251-74. PubMed ID: 3164248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma.
    De Rienzo A; Jhanwar SC; Testa JR
    Genes Chromosomes Cancer; 2000 Jul; 28(3):337-41. PubMed ID: 10862040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonrandom chromosome alterations in human malignant mesothelioma.
    Popescu NC; Chahinian AP; DiPaolo JA
    Cancer Res; 1988 Jan; 48(1):142-7. PubMed ID: 3334988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. del(6q) as a possible primary change in malignant mesothelioma.
    Meloni AM; Stephenson CF; Li FP; Sandberg AA
    Cancer Genet Cytogenet; 1992 Mar; 59(1):57-61. PubMed ID: 1555192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.
    Murthy SS; Testa JR
    J Cell Physiol; 1999 Aug; 180(2):150-7. PubMed ID: 10395284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent chromosome 6 abnormalities in malignant mesothelioma.
    Ribotta M; Roseo F; Salvio M; Castagneto B; Carbone M; Procopio A; Giordano A; Mutti L
    Monaldi Arch Chest Dis; 1998 Apr; 53(2):228-35. PubMed ID: 9689813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome changes in malignant mesothelioma.
    Gibas Z; Li FP; Antman KH; Bernal S; Stahel R; Sandberg AA
    Cancer Genet Cytogenet; 1986 Feb; 20(3-4):191-201. PubMed ID: 3943062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetic analysis of malignant mesothelioma.
    Hagemeijer A; Versnel MA; Van Drunen E; Moret M; Bouts MJ; van der Kwast TH; Hoogsteden HC
    Cancer Genet Cytogenet; 1990 Jul; 47(1):1-28. PubMed ID: 2357680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma.
    Prins JB; Williamson KA; Kamp MM; Van Hezik EJ; Van der Kwast TH; Hagemeijer A; Versnel MA
    Int J Cancer; 1998 Feb; 75(4):649-53. PubMed ID: 9466670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interphase cytogenetics on paraffin sections of malignant pleural mesothelioma. A comparison to conventional karyotyping and flow cytometric studies.
    Tiainen M; Hopman A; Moesker O; Ramaekers F; Wessman M; Laasonen A; Pyrhönen S; Tammilehto L; Mattson K; Knuutila S
    Cancer Genet Cytogenet; 1992 Sep; 62(2):171-9. PubMed ID: 1394105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytogenetic and fluorescence in situ hybridization characterization of chromosome 1 rearrangements in head and neck carcinomas delineate a target region for deletions within 1p11-1p13.
    Jin Y; Jin C; Wennerberg J; Mertens F; Höglund M
    Cancer Res; 1998 Dec; 58(24):5859-65. PubMed ID: 9865746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic genetic alterations in human malignant mesothelioma (review).
    Lee WC; Testa JR
    Int J Oncol; 1999 Jan; 14(1):181-8. PubMed ID: 9863027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of loss of 1p and alterations of chromosome 14 in meningioma progression.
    Lopez-Gines C; Cerda-Nicolas M; Gil-Benso R; Callaghan R; Collado M; Roldan P; Llombart-Bosch A
    Cancer Genet Cytogenet; 2004 Jan; 148(2):123-8. PubMed ID: 14734222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.